Markets:

Overview

News

Currencies

International

Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

115.07 UNCHANGED

Last Price Updated: 4:15 PM EDT, Apr 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗

May 18, 2026

This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.

Via The Motley Fool

Topics Regulatory Compliance

Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check

April 06, 2026

Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2,...

Via MarketMinute

Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution

March 31, 2026

In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines...

Via MarketMinute

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗

March 22, 2026

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer.

Via The Motley Fool

The Record-Breaking M&A Renaissance of 2026: Why Deal Values are Soaring as Volume Dips

March 19, 2026

As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic...

Via MarketMinute

Topics Artificial Intelligence Economy Workforce

Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

March 19, 2026

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation.

From Halper Sadeh LLC

Via GlobeNewswire

Halper Sadeh LLC is Investigating Whether SEM, UNF, ACLX, FONR are Obtaining Fair Deals for their Shareholders

March 17, 2026

From Halper Sadeh LLC

Via GlobeNewswire

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗

March 16, 2026

Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.

Via The Motley Fool

This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗

March 16, 2026

This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.

Via The Motley Fool

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

March 13, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Halper Sadeh LLC is Investigating Whether BCO, THR, ACLX are Obtaining Fair Deals for their Shareholders

March 05, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders

March 04, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement ↗

March 02, 2026

Arcellx shares have jumped 75% in 2026, but that's because the stock will soon be off the market.

Via The Motley Fool

Topics Regulatory Compliance

Arcellx President Sells $10M Worth of Shares After Acquisition Announcement ↗

March 02, 2026

Arcellx shares have jumped 75% in 2026, but that's because the stock will soon be off the market.

Via The Motley Fool

Topics Regulatory Compliance

Halper Sadeh LLC is Investigating Whether ACLX, EHAB, VRE are Obtaining Fair Deals for their Shareholders

February 24, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

February 23, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Let's take a look at the stocks that are in motion in today's session. ↗

February 23, 2026

Via Chartmill

Here are the top movers in Monday's session. ↗

February 23, 2026

Via Chartmill

These stocks are gapping in today's session ↗

February 23, 2026

Via Chartmill

These stocks are moving in today's pre-market session ↗

February 23, 2026

Via Chartmill

ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders

February 23, 2026

From Halper Sadeh LLC

Via Business Wire

Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗

February 23, 2026

Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal.

Via Stocktwits

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

February 23, 2026

From Arcellx, Inc.

Via Business Wire

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.

Via The Motley Fool

Topics Regulatory Compliance

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the...

Via Finterra

Topics Economy Intellectual Property

Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder

February 04, 2026

From Arcellx, Inc.

Via Business Wire

Arcellx Director Sells 6,000 Shares for $450,000 ↗

January 31, 2026

A director at one of the top clinical-stage biotech companies sold 6,000 insider shares towards the end of January 2026 amid the company's stock having an underwhelming performance in 2025.

Via The Motley Fool

Topics Regulatory Compliance

The Small-Cap M&A Boom of 2026: How $440 Billion in Dry Powder and Rate Cuts Are Remaking the Market

January 27, 2026

As of January 27, 2026, the financial landscape has undergone a dramatic transformation. After a prolonged "deal winter" that chilled the markets through 2023 and much of 2024, the small-cap sector is...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.